Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria

vesicles, which is applied in the field of pharmaceutical and food compositions containing extracellular vesicles derived from akkermansia muciniphila bacteria, can solve the problems of not knowing the mechanism of inhibiting the local inflammatory response caused by pathogenic bacteria-derived vesicles, no research finding that shows a metabolic disease such as obesity or diabetes can be alleviated or treated, etc., to achieve akkermansia muciniphila muciniphila muciniphila a technology of akkermansia muciniphila a technology of akkermansia muciniphila a technology of akkermansia muciniphila a technology of a metabolic disease and a technology of a metabolic disease and a technology of a metabolic disease and a technology of a drug and food composition and a technology of akkermansia muciniphila bacteria drug

Inactive Publication Date: 2017-03-30
MD HEALTHCARE INC
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is a pharmaceutical composition and a fermented food composition that contain Akkermansia muciniphila-derived extracellular vesicles (EVs). The composition can treat and prevent metabolic diseases associated with high fat diets, including obesity, diabetes, hyperlipidemia, hypertension, etc. The technical effect is the use of Akkermansia muciniphila-derived EVs in pharmaceutical and food compositions to prevent and alleviate metabolic diseases.

Problems solved by technology

However, a mechanism of inhibiting the local inflammatory response caused by pathogenic bacteria-derived vesicles is not known yet.
However, there is no research finding that shows a metabolic disease such as obesity or diabetes, etc. can be alleviated or treated by Akkermansia muciniphila-derived extracellular vesicles, not by Akkermansia muciniphila itself.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria
  • Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria
  • Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from akkermansia muciniphila bacteria

Examples

Experimental program
Comparison scheme
Effect test

example 1

Isolation of Extracellular Vesicles from Culture Medium of Akkermansia Muciniphila

[0056]An Akkermansia muciniphila strain (ATCC BAA-835) was cultured in 2 L of autoclaved Brain-heart infusion broth (BD 237500) in an anaerobic chamber for 72 hours so that an O.D value became 1.5, and then a culture medium was centrifuged at a high speed (10,000×g) for 20 minutes to obtain a supernatant excluding a precipitated bacterial cell pellet. The supernatant was filtered with a 0.45 μm filter and a 0.22 μm filter, thus obtaining a culture medium concentrated about 14 fold using the Quixstand benchtop system. The culture medium was ultracentrifuged (150,000 ×g) at 4° C. for 2 hours to obtain pellets, and then the pellets was dissolved with sterile saline (PBS), followed by protein quantification.

example 2

Characteristic Analysis of Extracellular Vesicles

[0057]In order to confirm whether the substance obtained by the method of Example 1 is Akkermansia muciniphila-derived extracellular vesicles, a 50 μg / ml sample obtained by quantifying proteins was observed through the JEM 1011 electron microscope (commercially available from Jeol Ltd., Japan). As a result, as shown in FIG. 1, it can be seen that the Akkermansia muciniphila-derived extracellular vesicle is spherical.

[0058]In addition, in order to confirm a size of an extracellular vesicle isolated from Akkermansia muciniphila using a dynamic light scattering (DLS) method, a 50 μg / ml sample was measured through the Zetasizer Nano ZS (commercially available from Malvern Instruments Ltd, UK). As a result, as shown in FIG. 2, it can be seen that Akkermansia muciniphila-derived extracellular vesicles have an average diameter of 20 to 300 nm.

[0059]In addition, in order to confirm a protein expression pattern of extracellular vesicles isolat...

example 3

Therapeutic Effects of Akkermansia Muciniphila-Derived Extracellular vesicles in obese and diabetic mouse induced by a high fat diet

[0061]In order to confirm whether the Akkermansia muciniphila-derived extracellular vesicles obtained in Example 1 inhibit obesity and diabetes induced by a high fat diet, an experiment was performed as follows.

[0062]The extracellular vesicles obtained in Example 1 were administered to each of normal mice which were fed a regular diet (RD) for 2 months and obese and diabetic mouse models induced by being fed a high fat diet (HFD) for 2 months at a dose of 10 μg / mouse for 3 weeks at two day intervals (See FIG. 5). In this case, a group of only RD-fed mice and a group of RD-fed and extracellular vesicle-administered mice were used as negative controls.

[0063]In a result obtained by measuring weight while extracellular vesicles are administered at two day intervals, as shown in FIG. 6, it can be seen that a weight was not increased for 3 weeks in a HFD-fed,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a pharmaceutical and food composition for treating, preventing, or alleviating a metabolic disease, containing, as an active ingredient, extracellular vesicles derived from Akkermansia muciniphila. The composition of the present invention can be used as a pharmaceutical / food composition and the like for treating, preventing, or alleviating metabolic diseases, in particular metabolic diseases such as obesity, diabetes, hyperlipidemia, arteriosclerosis, and hypertension, occurring or exacerbated due to a high fat diet. In addition, in the present invention, a fermented food itself, prepared by adding Akkermansia muciniphila, can be used for the purpose of preventing or alleviating a metabolic disease occurring or exacerbated due to a high fat diet.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to and the benefit of Korean Patent Application No. 10-2014-0060409, filed on May 20, 2014, Korean Patent Application No. 10-2015-0068864, filed on May 18, 2015, and International Patent Application No. PCT / KR2015 / 004983, filed on May 19, 2015, the disclosures of which are incorporated herein by reference in their entirety.TECHNICAL FIELD[0002]The present invention relates to a pharmaceutical and food composition containing extracellular vesicles derived from Akkermansia muciniphila as an active ingredient for treating, preventing or alleviating a metabolic disease.BACKGROUND ART[0003]A metabolic disease is a general term for diseases that occur due to in vivo metabolic disorders. The metabolic disease generally is caused by the imbalance of carbohydrates, lipids, proteins, vitamins, electrolytes, water, and the like. Examples of the metabolic diseases include obesity, diabetes, hyperlipidemia, arterioscle...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/74A23L33/135
CPCA61K35/74A23V2002/00A23L33/135A23L33/10A61P3/04A61P3/06A61P43/00A61P9/10A61P9/12A61P3/10
Inventor KIM, YOON-KEUNPARK, HYUN-TAEK
Owner MD HEALTHCARE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com